Ravi Salgia,

• 1987, M.D., Loyola University School of Medicine, Chicago, IL

• 1988-1990, Internal Medicine Resident, The Johns Hopkins Hospital, Baltimore, MD

Dr. Ravi Salgia, MD, PhD, serves as the Arthur & Rosalie Kaplan Chair in Medical Oncology and leads the Department of Medical Oncology & Therapeutics Research at City of Hope^® Cancer Center Duarte, where he oversees a team of over 100 oncology faculty members engaged in both clinical excellence and translational research. 

Before his leadership role at City of Hope, Dr. Salgia held multiple positions at the University of Chicago, including director of the Thoracic Oncology Program and Aerodigestive Tract Program Translational Research Lab. He was also vice chair for translational research in the Department of Medicine and associate director for translational science at the University’s Comprehensive Cancer Center. Earlier in his career, he spent a decade at Dana-Farber Cancer Institute and Harvard Medical School, where he rose from instructor to assistant professor of medicine. 

Dr. Salgia brings an interdisciplinary academic foundation, having earned a summa cum laude undergraduate degree in mathematics, biology, and chemistry, followed by both an M.D. and Ph.D. from Loyola University Chicago. He pursued postdoctoral training in neurochemistry and physiology, completed his internal medicine residency at Johns Hopkins, and trained in medical oncology at Dana-Farber while also serving as a clinical fellow at Harvard Medical School. 

Board-certified in medical oncology, Dr. Salgia is a prominent investigator in thoracic malignancies and molecular oncology, serving on multiple National Cancer Institute panels. He is co-chief editor of Journal of Carcinogenesis, on the editorial boards of several journals, and has authored more than 550 scientific publications, including three books and over 30 book chapters. He holds several patents related to oncogenic targets and novel therapeutics. 

His research has been continually supported by the NIH and recognized through numerous honors including the πμε National Mathematics Award, the Richard V. Andree Award, and the Asclepius Award for lung cancer leadership. He serves on the board of directors for the National Comprehensive Cancer Network and is active with the American Lung Association and CI4CC. Dr. Salgia remains committed to fostering the next generation of clinician-scientists and advancing collaborative, cross-disciplinary cancer research.